Ryan Barbara 4

What Happened Barbara Ryan, a director of MiNK Therapeutics, sold a total of 1,500 shares of INKT common stock in two open-market transactions on June 4, 2026. The filings report 500 shares sold at $12.68 (reported value $6,342) and 1,000 shares sold at $12.80 (reported value $12,800), for a combined reported proceeds of $19,142. These were sales (not purchases); sales of vested or awarded shares by board members are often routine liquidity events.

Key Details

• Transaction date: June 4, 2026
• Sales: 500 shares @ $12.68 (reported $6,342); 1,000 shares @ $12.80 (reported $12,800)
• Total reported proceeds: $19,142
• Shares owned after transaction: Not disclosed in this Form 4
• Footnote: The sold shares were common stock Ms. Ryan received as compensation for Board services (per footnote F1)
• Filing: Form 4 filed June 5, 2026 (appears timely; transaction reported the next day)
• Transaction code: S (Sale)

Context The filing indicates these were previously issued/received shares sold for cash, not an option exercise or a gift. Because the shares were received as director compensation, the sale reflects monetization of board pay rather than a straightforward buy/sell signal about company prospects. For many retail investors, purchases are generally more informative than routine sales by non-executive directors; this filing should be viewed as a disclosure of director liquidity rather than a direct endorsement or repudiation of company outlook.